Showing 581 - 600 results of 697 for search '"pharmacy"', query time: 0.06s Refine Results
  1. 581
  2. 582
  3. 583
  4. 584
  5. 585
  6. 586
  7. 587
  8. 588

    Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation by Li Wang, Elyse Fritschel, Onur Baser

    Published 2013-11-01
    “…**Methods:** This was a retrospective analysis of medical and pharmacy claims of NVAF patients from a large commercial health insurance database (01/01/2005-12/31/2007). …”
    Get full text
    Article
  9. 589

    Glycogen Storage Disease Type Ia: A Retrospective Claims Analysis of Complications, Resource Utilization, and Cost of Care by Eliza Kruger, Justin Nedzesky, Nina Thomas, Jeffrey D. Dunn, Andrew A. Grimm

    Published 2025-01-01
    “…Healthcare use and costs were assessed by setting of care (inpatient, outpatient, physician office, emergency department, and pharmacy). **Results:** Overall, 557 patients with GSDIa and 5570 matched comparators (male, 63%; adults, 67%) were identified. …”
    Get full text
    Article
  10. 590

    Exploring drug utilization patterns, healthcare resource utilization, and epidemiology of rheumatoid arthritis in Colombia: a retrospective claims database study by Daniel G. Fernández-Ávila, Monica Betancur, Amira Kronfly, Edwin Jáuregui

    Published 2025-02-01
    “…We estimated the age-standardized incidence and prevalence of RA each year, drug utilization patterns for disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids, rates of medical consultations, emergency room visits, and hospitalizations, and associated comorbidities and healthcare-related and pharmacy-related costs. Results Overall, 327,430 unique patients with RA between 2017 and 2022 were included in the analysis, comprising 94,093 incident cases and 722,569 prevalent cases. …”
    Get full text
    Article
  11. 591
  12. 592
  13. 593

    Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population by Dingwei Dai, Ajay Sharma, Amy L. Phillips, Carroline Lobo

    Published 2022-11-01
    “…Eligibility criteria were (1) at least 3 MS-related inpatient/outpatient (ICD-10-CM: G35), or disease-modifying therapy claims within 1 year (date of first claim = index date); (2) Aetna commercial health plan or Medicare Advantage medical and pharmacy benefits at least 12 months pre-/post-index; and (3) age 18 and older. …”
    Get full text
    Article
  14. 594
  15. 595
  16. 596
  17. 597
  18. 598
  19. 599
  20. 600

    Quzhou Aurantii Fructus Flavonoids Ameliorate Inflammatory Responses, Intestinal Barrier Dysfunction in DSS-Induced Colitis by Modulating PI3K/AKT Signaling Pathway and Gut Microbi... by Wang H, Huang W, Pan X, Tian M, Chen J, Liu X, Li Q, Qi J, Ye Y, Gao L

    Published 2025-02-01
    “…Haiou Wang,1 Wenkang Huang,1 Xiaoya Pan,1 Meizi Tian,1 Jiahui Chen,1 Xiaotong Liu,1 Qin Li,1 Jianhua Qi,2 Yiping Ye,1 Lijuan Gao1 1School of Pharmacy, Hangzhou Medical College, Hangzhou, 310013, People’s Republic of China; 2College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People’s Republic of ChinaCorrespondence: Lijuan Gao; Yiping Ye, Hangzhou Medical College, 182 Tianmushan Road, Hangzhou, Zhejiang, 310013, People’s Republic of China, Email gaolijuan04141002@126.com; yeyiping2005@163.comPurpose: To explore the protective effect and underlying mechanism of Quzhou Aurantii Fructus flavonoids (QAFF) on Ulcerative colitis (UC).Methods: The constituents of QAFF were accurately determined by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). …”
    Get full text
    Article